Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open Label Extension Study of Conatumumab and AMG 479

NCT01327612 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01327612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01327612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open Label Extension Study of Conatumumab and AMG 479
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
March 3, 2011
Completion date
February 5, 2020
Enrollment
12 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, carcinoid, colorectal cancer, locally advanced, lymphoma, metastatic cancer, non-small cell lung cancer, sarcoma, solid tumors